GSK to acquire Aiolos Bio for $1bn
Betsy Goodfellow | January 9, 2024 | News story | Business Services | Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an initial $1bn upfront payment along with up to $400m in success-based regulatory milestone payments.
Aiolos is a clinical-stage biopharmaceutical company with a focus on the treatment of patients with certain respiratory and inflammatory conditions.
This acquisition will allow GSK to access Aiolos’s AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody which is ready to enter phase 2 clinical development for the treatment of adult patients with asthma, although there are other potential additional indications such as chronic rhinosinusitis with nasal polyps.
By gaining AIO-001, GSK intends to expand its respiratory portfolio to provide an option of a biologic to treat a wider selection of patients living with asthma.
Tony Wood, chief scientific officer at GSK, commented: “We have a proud heritage and deep development expertise in respiratory medicines, especially addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation. Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.”
Betsy Goodfellow
Related Content
GSK pledges £45m to Fleming Initiative to fight AMR
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first …
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …